Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1148342

registered interest
date	04/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential merits of extending provision of genetic testing to all people diagnosed with breast cancer.
tabling member constituency	Wolverhampton North East
tabling member printed	Emma Reynolds
uin	294698
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>The NHS Long Term Plan sets out the ambition to extend the use of molecular diagnostics and, over the next 10 years, to routinely offer genomic testing to all people with cancer for whom it would be of clinical benefit.</p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 08/10/2019 14:50:57 answering member 4380 label Biography information for Jo Churchill
tabling member	4077 label Biography information for Emma Reynolds

1148350

registered interest
date	04/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect on testing timeframes of changes being made to the provision of molecular pathology testing in cancer care and treatment.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	294725
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>NHS England is mobilising the Genomic Medicine Service which brings together existing clinical genetics services and the new genomic laboratory infrastructure. By consolidating genomic testing services into seven Genomic Laboratory Hubs (GLHs), the National Health Service is able to operate more efficiently using cutting-edge high throughput technology and supporting make equitable access. The new service will enable additional genomic information to inform treatment and enable turnaround times to be kept to a minimum.</p><p>The turnaround times which are set out in the GLH service specification fall within the existing 62 day standard for receiving first treatment for cancer.</p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 08/10/2019 14:51:32 answering member 4380 label Biography information for Jo Churchill
tabling member	4244 label Biography information for Jonathan Ashworth

1148366

registered interest
date	04/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners: Rural Areas
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made on recruiting additional GPs in rural locations.
tabling member constituency	Woking
tabling member printed	Mr Jonathan Lord
uin	294707
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 08/10/2019 15:20:25 answering member 4380 label Biography information for Jo Churchill
tabling member	4090 label Biography information for Mr Jonathan Lord

1148368

registered interest
date	04/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners: Surrey
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to maintain the level of out-of-hours GP cover in Surrey.
tabling member constituency	Woking
tabling member printed	Mr Jonathan Lord
uin	294709
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 08/10/2019 15:17:15 answering member 4380 label Biography information for Jo Churchill
tabling member	4090 label Biography information for Mr Jonathan Lord

1148153

registered interest
date	03/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cervical Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce waiting times for cervical screening test results.
tabling member constituency	Woking
tabling member printed	Mr Jonathan Lord
uin	294162
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 08/10/2019 15:25:04 answering member 4380 label Biography information for Jo Churchill
tabling member	4090 label Biography information for Mr Jonathan Lord

1148154

registered interest
date	03/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hepatitis: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to improve the detection of hepatitis B and C.
tabling member constituency	Woking
tabling member printed	Mr Jonathan Lord
uin	294163
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 08/10/2019 15:22:33 answering member 4380 label Biography information for Jo Churchill
tabling member	4090 label Biography information for Mr Jonathan Lord

1148158

registered interest
date	03/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Mortality Rates
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the mortality rate was for people under 75 years of age with cancer in each of the last three years.
tabling member constituency	Woking
tabling member printed	Mr Jonathan Lord
uin	294166
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>The directly age-standardised cancer mortality rates per 100,000 population in England under 75 years of age for each of the three most recently published years are shown in the following table:</p><table><tbody><tr><td><p>Year</p></td><td><p>Mortality rate</p></td></tr><tr><td><p>2015</p></td><td><p>136.4</p></td></tr><tr><td><p>2016</p></td><td><p>135.6</p></td></tr><tr><td><p>2017</p></td><td><p>131.8</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 08/10/2019 14:47:15 answering member 4380 label Biography information for Jo Churchill
tabling member	4090 label Biography information for Mr Jonathan Lord

1148207

registered interest
date	03/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Parkinson's Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with health bodies on the findings of recent clinical trials for Terazosin and its potential effect of slowing down the progression of Parkinson's disease.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	294171
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 08/10/2019 15:21:50 answering member 4380 label Biography information for Jo Churchill
tabling member	4131 label Biography information for Jim Shannon

1148211

registered interest
date	03/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Stargardt Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people were diagnosed with Stargardt Disease in the last five years.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	294173
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 08/10/2019 15:19:26 answering member 4380 label Biography information for Jo Churchill
tabling member	4131 label Biography information for Jim Shannon

1148212

registered interest
date	03/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Glaucoma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to make the biodegradable implant that replaces eye drops for glaucoma available on the NHS.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	294174
answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>Decisions about treatment should always be based on patients’ clinical needs. Clinical commissioning groups (CCGs) are required to commission healthcare services that meet the needs of their local population. To achieve this, they must assess local need, determining priorities and strategies, and commission services on behalf of their local population; overseeing those contracts to ensure high-quality care is provided.</p><p>National Health Service commissioners are legally required to fund treatments recommended in National Institute for Health and Care Excellence technology appraisal and highly specialised technologies guidance.</p><p>The future routine availability of any new or novel treatments would be subject to large scale clinical trials demonstrating the safety and efficacy of the treatment approach and subsequent assessments of its cost effectiveness for routine use.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 08/10/2019 14:46:07 answering member 4380 label Biography information for Jo Churchill
tabling member	4131 label Biography information for Jim Shannon